Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

1. juni 2015 opdateret af: Boehringer Ingelheim

Observational Study Assessing the Safety, Efficacy and Treatment Adherence of Nevirapine Extended Release (Combined With Other Antiretroviral Drugs) in HIV Infected Patients in Daily Clinical Practice

This Post Marketing Surveillance study will be performed as an open-label, prospective, non-interventional, uncontrolled study in Human immunodeficit Virus-1 (HIV-1) infected patients. Data will only be documented in patients for whom a pharmacotherapy with nevirapine extended release is initiated. Both anti-retroviral therapy (ART) naïve patients and pre-treated patients switching from nevirapine immediate release or other anti-retroviral therapy (ART) will be included in the study. The decision to initiate treatment with nevirapine extended release is independent of this study and is based entirely on individual patient need and the judgement of the treating physician. The aim of the study is to assess the safety and efficacy and treatment adherence of nevirapine extended release in HIV-1 infected patients in routine clinical practice. It is planned to document five visits for each patient over a twenty four week observational period.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

Study Design:

non-interventional uncontrolled observational study

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

398

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Polen
      • Bialystok, Polen
        • Boehringer Ingelheim Investigational Site 8
      • Bialystok, Polen
        • Boehringer Ingelheim Investigational Site 7
      • Bydgoszcz, Polen
        • Boehringer Ingelheim Investigational Site 9
      • Bydgoszcz, Polen
        • Boehringer Ingelheim Investigational Site 10
      • Chorzów, Polen
        • Boehringer Ingelheim Investigational Site 11
      • Chorzów, Polen
        • Boehringer Ingelheim Investigational Site 12
      • Gdañsk, Polen
        • Boehringer Ingelheim Investigational Site 13
      • Gdañsk, Polen
        • Boehringer Ingelheim Investigational Site 14
      • Gdañsk, Polen
        • Boehringer Ingelheim Investigational Site 15
      • Kraków, Polen
        • Boehringer Ingelheim Investigational Site 16
      • Kraków, Polen
        • Boehringer Ingelheim Investigational Site 17
      • Poznañ, Polen
        • Boehringer Ingelheim Investigational Site 18
      • Wroc£aw, Polen
        • Boehringer Ingelheim Investigational Site 19
      • Wroc£aw, Polen
        • Boehringer Ingelheim Investigational Site 20
  • Rumænien
      • Bacau, Rumænien
        • Boehringer Ingelheim Investigational Site 50
      • Brasov, Rumænien
        • Boehringer Ingelheim Investigational Site 51
      • Brasov, Rumænien
        • Boehringer Ingelheim Investigational Site 52
      • Brasov, Rumænien
        • Boehringer Ingelheim Investigational Site 53
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 21
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 22
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 23
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 24
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 25
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 26
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 27
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 28
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 29
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 30
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 31
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 32
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 33
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 34
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 35
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 36
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 37
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 38
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 39
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 40
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 41
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 42
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 43
      • Bucuresti, Rumænien
        • Boehringer Ingelheim Investigational Site 44
      • Constanta, Rumænien
        • Boehringer Ingelheim Investigational Site 46
      • Constanta, Rumænien
        • Boehringer Ingelheim Investigational Site 47
      • Constanta, Rumænien
        • Boehringer Ingelheim Investigational Site 48
      • Giurgiu, Rumænien
        • Boehringer Ingelheim Investigational Site 45
      • Ploiesti, Rumænien
        • Boehringer Ingelheim Investigational Site 49
  • Østrig
      • Graz, Østrig
        • Boehringer Ingelheim Investigational Site 6
      • Salzburg, Østrig
        • Boehringer Ingelheim Investigational Site 5
      • Vienna, Østrig
        • Boehringer Ingelheim Investigational Site 1
      • Vienna, Østrig
        • Boehringer Ingelheim Investigational Site 2
      • Vienna, Østrig
        • Boehringer Ingelheim Investigational Site 3
      • Wels, Østrig
        • Boehringer Ingelheim Investigational Site 4

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 64 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Sandsynlighedsprøve

Studiebefolkning

HIV-1 infected patients

Beskrivelse

Inclusion criteria:

  1. HIV-1 infected male and female 18 years and above;
  2. anti-retroviral therapy (ART) naive and pre-treated patients switching from a nevirapine immediate release or other ART.

Exclusion criteria:

Consistent with the current VIRAMUNE prolonged release SPC.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
nevirapine extended release

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Patients Reporting Non-serious Adverse Events, Serious Adverse Events, and Non-serious and Serious Adverse Events Leading to Treatment Discontinuation
Tidsramme: up to 72 weeks
The primary endpoint is to evaluate the safety of a highly active antiretroviral therapy (HAART) that includes nevirapine extended release in routine clinical practice which is to assess the number of patients reporting non-serious adverse events (nSAEs), the number of patients with serious adverse events (SAE), the number of patients with non-serious adverse events leading to treatment discontinuation, and the number of patients with serious adverse events leading to discontinuation.
up to 72 weeks
Number of Patients Reporting Rash of Any Severity
Tidsramme: up to 72 weeks
Number of patients reporting rash of any severity as adverse event
up to 72 weeks
Number of Patients Reporting Hepatic Events
Tidsramme: up to 72 weeks
Number of patients reporting hepatic events either as adverse event (AE) or as laboratory abnormality of Grade 1 to Grade 4 in aspartate aminotransferase (AST), alanine transaminase (ALT), Gamma-Glutamyl-Transferase (Gamma-GT) and bilirubin.
up to 72 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Patients With Virologic Response at Week 24 (Viral Load <50 Copies/mL)
Tidsramme: 24 weeks
Virologic response is defined as confirmed Human Immunodeficiency Virus (HIV) viral load of < 50 copies/mL (at two consecutive measurements after baseline) up to week 24 and without subsequent rebound or change of anti-retroviral (ARV) therapy up to week 24. A rebound is defined as two consecutive measurements of viral load (VL) ≥ 50 copies/mL, at least two weeks apart, after two consecutive measurements of VL< 50 copies/mL. A change of ARV therapy is defined as a permanent discontinuation of nevirapine extended release, addition of new ARV drugs, or alteration in background therapy. A change in the background therapy due to toxicity or intolerance is not considered as treatment failure. If no follow-up viral load was available the virologic response is Missing.
24 weeks
Change in CD4+ Cell Count From Baseline to Week 24
Tidsramme: baseline and week 24
The change in the Cluster of differentiation 4 (CD4+) cell count from baseline after 24 weeks was calculated by subtracting the baseline value from the value after 24 weeks. Therefore, a positive change represents an increase in CD4+ cell count.
baseline and week 24
Change in Morisky Medication Adherence Scale Score From Baseline to 24 Weeks
Tidsramme: baseline and week 24
The Morisky Medication Adherence scale (MMAS-8 scale) is a recognized indicator of medication adherence, consisting of 8 questions with a sum score ranging between 0 and 8 points. The higher score indicates higher adherence to the prescribed therapy recommendation. It has been agreed that the score of 8 could be categorized as having high adherence, score between 6 and 7 as medium adherence and scores of 5 and less as low adherence. The change is presented as the score after 24 weeks minus the score at baseline. Therefore, a positive change score reflects an improvement in the adherence.
baseline and week 24
Number of Patients Reporting Once Daily Nevirapine Intake More Convenient Than Twice Daily Formulation
Tidsramme: 24 weeks
The number of patients reporting that they find the once daily nevirapine intake more / very much more convenient than the twice daily formulation.
24 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Boehringer Ingelheim

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. marts 2012

Primær færdiggørelse (Faktiske)

1. maj 2014

Studieafslutning (Faktiske)

1. maj 2014

Datoer for studieregistrering

Først indsendt

17. januar 2012

Først indsendt, der opfyldte QC-kriterier

31. januar 2012

Først opslået (Skøn)

2. februar 2012

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

2. juni 2015

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. juni 2015

Sidst verificeret

1. juni 2015

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 1100.1550

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med HIV-infektioner

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Cameroon

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner